BACKGROUND: Eclampsia is a major cause of maternal and perinatal morbidity and mortality. Magnesium sulphate is currently the gold standard in the management of eclamptic fit. As a result of its toxicity, current efforts are being geared towards discovering a lower dosage without compromising its efficacy. OBJECTIVE: To compare the effectiveness of low-dose magnesium sulphate and standard Pritchard regimen in controlling eclamptic fit and preventing adverse maternal and neonatal outcomes in eclamptic patients that were managed in Obafemi Awolowo University Teaching Hospitals Complex, Ile Ife. METHODOLOGY: This study was a randomized double-blind clinical trial comparing lowdose magnesium sulphate with standard Pritchard regimen. Twenty-eight patients (the cases) randomized into low-dose regimen group received 4g loading dose, intravenously and a maintenance dose of 0.6g/hr through intravenous infusion for a period of 24 hours post-delivery or after the last fit. The control arm of the study were twenty eight patients who had the Pritchard regimen comprising of a loading dose of 14g followed by maintenance dose of 5g 4 hourly for a period of 24 hours post-delivery or after the last fit. In both study groups, additional 2g of intravenously magnesium sulphate was given for recurrent convulsions. Outcome measures includes: recurrent convulsion, apgar score, perinatal death and maternal complications including death.